A Phase 2 interventional study of VIR-2218 and Placebo in Hepatitis B, Chronic, sponsored by Brii Biosciences Limited. Completed at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-08-26.
Sponsored by Brii Biosciences Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 375 studies in Hepatitis B, Chronic with a site in China — 89 open to participants now, 110 under way, 7 of them phase 3. Hepatitis B, Chronic · China.
Among the 375 studies in Hepatitis B, Chronic with a site in China, this one is the 255th largest by enrollment of the 273 interventional ones that give a count, is one of 29 that started in 2020, is one of 72 in phase 2, and was the 198th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →89 of the 375 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:
Jiyan Liu · Sites in China
Ages 18–65
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Fujian Akeylink Biotechnology Co., Ltd. · Sites in China
Ages 35–65
Ausper Biopharma Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Zhiliang Gao · Sites in China
Ages 18–65 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
375 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 62 · Phase 2 85 · Phase 3 27 · Phase 4 73
First in 2000; this study’s year is marked. 29 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 120 across the 273 interventional studies, 500 across the 99 observational. Of the 151 that completed or were terminated, 29 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
167 of 375 have an industry lead sponsor. The 10 most frequent:
Brii Biosciences Limited is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Brii Biosciences Limited has 5 studies filed under Hepatitis B, Chronic — fewer than ten, so there is no comparison to draw.
39 of the studies in Hepatitis B, Chronic with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07090759Phase 3Fujian Akeylink Biotechnology Co., Ltd.To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment | 2026-12-01 |
| NCT07246889Phase 3Ausper Biopharma Co., Ltd.Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) | 2026-12-18 |
| NCT07307586Phase 3Zhigang RenA Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B | 2026-12-31 |
| NCT07203118Phase 3Xi'an Xintong Pharmaceutical Research Co.,Ltd.A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B | 2027-06-30 |
| NCT02863757Humanity and Health Research CentreFollow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease | 2026-12 |
Add all 39 to your calendar (.ics) → With an account.
Among the 375 studies in Hepatitis B, Chronic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the safety, pharmacokinetics characteristics, and antiviral activities of multiple doses of VIR-2218 in adults with chronic HBV infection in mainland China.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: VIR-2218 VIR-2218 given by subcutaneous injection
Drug: VIR-2218
Drug: Placebo Saline given by subcutaneous injection
Drug: Placebo
VIR-2218 given by subcutaneous injection
Saline given by subcutaneous injection
Incidence of Treatment-emergent Adverse Events (TEAEs)
Number of participants with treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0 are summarized by cohort. Incidence is defined as the number of participants with TEAEs in relation to the total number of participants in the cohort. TEAEs are defined as any AEs with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug.
Time frame: up to 48 weeks
Clinical Assessments Including But Not Limited to Laboratory Test Results
Number of participants with graded hematology, coagulation, chemistry abnormalities, and clinically significant abnormalities in vital signs and ECGs
Time frame: up to 48 weeks
PK: Maximum Plasma Concentration
VIR-2218 and metabolite maximum plasma concentrations (ng/mL) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.
Time frame: Maximum plasma concentrations were calculated based on all above results for Day 1 and Day 29 (Week 4).
PK: Time to Reach Maximum Plasma Concentration
VIR-2218 and metabolite time to Cmax (h) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.
Time frame: Time to Cmax were calculated based on all above results for Day 1 and Day 29 (Week 4).
PK: Area Under the Plasma Concentration Versus Time Curve to Last Measurable Timepoint
VIR-2218 and metabolite area under the curve from time 0 to last measurable time (ng\*h/mL) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.
Time frame: Area under the curve were calculated based on all above results for Day 1 and Day 29 (Week 4).
PK: Area Under the Plasma Concentration Versus Time Curve to Infinity
VIR-2218 and metabolite area under the curve from time 0 to infinity (ng\*h/mL) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.
Time frame: Area under the curve were calculated based on all above results for Day 1 and Day 29 (Week 4).
PK: Percent of Area Extrapolated From AUC Last to Infinity
VIR-2218 and metabolite percent of area extrapolated from AUC last to infinity (%) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.
Time frame: Percent of area extrapolated from AUC last to infinity were calculated based on all above results for Day 1 and Day 29 (Week 4).
PK: Apparent Terminal Elimination Half-life
VIR-2218 and metabolite apparent terminal elimination half-life (h) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.
Time frame: Apparent terminal elimination half-life were calculated based on all above results for Day 1 and Day 29 (Week 4).
PK: Apparent Plasma Clearance
VIR-2218 and metabolite apparent plasma clearance CL/F (mL/h) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.
Time frame: Apparent plasma clearance were calculated based on all above results for Day 1 and Day 29 (Week 4).
PK: Apparent Volume of Distribution
VIR-2218 and metabolite apparent volume of distribution Vz/F (mL) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.
Time frame: Apparent volume of distribution were calculated based on all above results for Day 1 and Day 29 (Week 4).
Maximum Change of Serum HBsAg From Baseline
Maximum change of serum HBsAg from Day 1 until 12 weeks post last dose (negative values mean reductions from baseline, positive values mean increased from baseline)
Time frame: up to 16 weeks
Number of Participants With Serum HBsAg Loss
Number of participants with serum HBsAg \< 0.05 IU/mL at two or more consecutive measurements
Time frame: up to 48 weeks
Number of Participants With Sustained Serum HBsAg Loss for at Least 6 Months
Number of participants with sustained serum HBsAg \< 0.05 IU/mL at all visits for at least 6 months
Time frame: up to 48 weeks
Number of Participants With Anti-HBs Seroconversion at Any Timepoint
Anti-HBs seroconversion is defined as anti-HBs positivity at two or more consecutive measurements
Time frame: up to 48 weeks
For HBeAg-positive Subjects: Number of Subjects With HBeAg Loss and/or Anti-HBe Seroconversion at Any Timepoint
HBeAg loss is defined as quantitative HBeAg \< 0.14 IU/mL at two or more consecutive measurements. Anti-HBe seroconversion is defined as anti-HBe positivity at two or more consecutive measurements.
Time frame: up to 48 weeks
| Milestone | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 1: Placebo | Part 2: VIR-2218 50mg | Part 2: VIR-2218 100 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 3 | 4 | 4 | 2 |
| Dosed | 4 | 4 | 3 | 4 | 4 | 2 |
| Completed | 3 | 3 | 3 | 4 | 3 | 2 |
| Not completed | 1 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 |
Number of participants with treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0 are summarized by cohort. Incidence is defined as the number of participants with TEAEs in relation to the total number of participants in the cohort. TEAEs are defined as any AEs with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug.
| Participants | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 1: Placebo | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Any TEAEs | 1 | 2 | 0 | 2 | 1 | 1 |
| Any TEAEs of CTCAE Grade 1 | 0 | 1 | 0 | 2 | 1 | 1 |
| Any TEAEs of CTCAE Grade 2 | 1 | 1 | 0 | 0 | 0 | 0 |
| Any TEAEs of CTCAE Grade 3 or above | 0 | 0 | 0 | 0 | 0 | 0 |
| Any drug related TEAEs | 0 | 0 | 0 | 1 | 1 | 0 |
| Any serious TEAEs | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with graded hematology, coagulation, chemistry abnormalities, and clinically significant abnormalities in vital signs and ECGs
| Participants | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 1: Placebo | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Any post baseline laboratory abnormalities of CTCAE Grade 1 | 4 | 4 | 2 | 2 | 4 | 2 |
| Any post baseline laboratory abnormalities of CTCAE Grade 2 or above | 0 | 0 | 0 | 0 | 0 | 0 |
| Any clinically significant vital signs | 0 | 0 | 0 | 0 | 0 | 0 |
| Any clinically significant ECGs | 0 | 0 | 0 | 0 | 0 | 0 |
VIR-2218 and metabolite maximum plasma concentrations (ng/mL) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.
| ng/mL | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg |
|---|---|---|---|---|
| VIR-2218 Cmax (Day 1) | 120 ± 40.5 | 144 ± 100.5 | 65.8 ± 58.6 | 260 ± 90.4 |
| VIR-2218 Cmax (Day 29) | 125 ± 48.8 | 198 ± 52.9 | 76.5 ± 35.7 | 268 ± 43.0 |
| AS(N-1)3'VIR-2218 Cmax (Day 1) | 10.2 ± NA | 31.4 ± NA | — | 28.1 ± 171.1 |
| AS(N-1)3'VIR-2218 Cmax (Day 29) | 16.3 ± NA | 23.6 ± 48.8 | 9.75 ± 1.1 | 19.3 ± 82.1 |
VIR-2218 and metabolite time to Cmax (h) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.
| hour | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg |
|---|---|---|---|---|
| VIR-2218 Tmax (Day 1) | 4.99 (1.88 to 8.03) | 2.00 (0.967 to 8.08) | 4.02 (4.00 to 7.80) | 4.00 (4.00 to 7.58) |
| VIR-2218 Tmax (Day 29) | 7.76 (1.08 to 8.13) | 4.02 (2.00 to 7.85) | 2.50 (0.967 to 4.00) | 5.93 (1.00 to 8.02) |
| AS(N-1)3'VIR-2218 Tmax (Day 1) | 7.95 (3.98 to 8.05) | 4.98 (2.03 to 7.92) | 7.80 (7.80 to 7.80) | 5.79 (4.00 to 22.1) |
| AS(N-1)3'VIR-2218 Tmax (Day 29) | 7.76 (4.05 to 8.13) | 5.93 (2.00 to 8.03) | 4.00 (4.00 to 4.00) | 5.93 (4.00 to 8.02) |
VIR-2218 and metabolite area under the curve from time 0 to last measurable time (ng\*h/mL) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.
| ng*h/mL | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg |
|---|---|---|---|---|
| VIR-2218 AUClast (Day 1) | 1080 ± 25.3 | 1400 ± 115.6 | 626 ± 31.1 | 3190 ± 42.3 |
| VIR-2218 AUClast (Day 29) | 854 ± 34.2 | 2390 ± 26.6 | 580 ± 56.9 | 3140 ± 15.8 |
| AS(N-1)3'VIR-2218 AUClast (Day 1) | 58.7 ± 28.9 | 159 ± 30.5 | 67.6 ± 2.1 | 180 ± 63.4 |
| AS(N-1)3'VIR-2218 AUClast (Day 29) | 50.2 ± 52.5 | 140 ± 81.2 | 63.1 ± 6.1 | 155 ± 39.8 |
VIR-2218 and metabolite area under the curve from time 0 to infinity (ng\*h/mL) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.
| ng*h/mL | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg |
|---|---|---|---|---|
| VIR-2218 AUCinf (Day 1) | — | 2820 ± 16.7 | — | — |
| VIR-2218 AUCinf (Day 29) | — | 2570 ± NA | 1210 ± NA | 3530 ± NA |
VIR-2218 and metabolite percent of area extrapolated from AUC last to infinity (%) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.
| % of AUCinf | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg |
|---|---|---|---|---|
| VIR-2218 %AUCextrap (Day 1) | — | 2.69 ± 5.1 | — | — |
| VIR-2218 %AUCextrap (Day 29) | 46.2 ± NA | 13.8 ± NA | 23.9 ± 263.4 | 5.88 ± NA |
| AS(N-1)3'VIR-2218 %AUCextrap (Day 29) | — | 49.2 ± NA | — | — |
VIR-2218 and metabolite apparent terminal elimination half-life (h) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.
| hour | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg |
|---|---|---|---|---|
| VIR-2218 t1/2 (Day 1) | — | 4.16 (4.10 to 4.22) | — | — |
| VIR-2218 t1/2 (Day 29) | — | 7.66 (7.66 to 7.66) | 6.53 (6.53 to 6.53) | 5.49 (5.49 to 5.49) |
VIR-2218 and metabolite apparent plasma clearance CL/F (mL/h) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.
| mL/h | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg |
|---|---|---|---|---|
| VIR-2218 CL/F (Day 1) | — | 35400 ± 16.7 | — | — |
| VIR-2218 CL/F (Day 29) | — | 39000 ± NA | 41300 ± NA | 28300 ± NA |
VIR-2218 and metabolite apparent volume of distribution Vz/F (mL) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.
| mL | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg |
|---|---|---|---|---|
| VIR-2218 Vz/F (Day 1) | — | 213000 ± 18.6 | — | — |
| VIR-2218 Vz/F (Day 29) | — | 431000 ± NA | 389000 ± NA | 224000 ± NA |
Maximum change of serum HBsAg from Day 1 until 12 weeks post last dose (negative values mean reductions from baseline, positive values mean increased from baseline)
| log10 IU/mL | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 1: Placebo | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Maximum Change of Serum HBsAg From Baseline | -1.064 ± 0.1047 | -1.346 ± 0.5169 | -0.049 ± 0.0158 | -0.793 ± 0.1017 | -1.268 ± 0.1693 | -0.120 ± 0.0826 |
Number of participants with serum HBsAg \< 0.05 IU/mL at two or more consecutive measurements
| Participants | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 1: Placebo | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Number of Participants With Serum HBsAg Loss | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with sustained serum HBsAg \< 0.05 IU/mL at all visits for at least 6 months
| Participants | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 1: Placebo | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Number of Participants With Sustained Serum HBsAg Loss for at Least 6 Months | 0 | 0 | 0 | 0 | 0 | 0 |
Anti-HBs seroconversion is defined as anti-HBs positivity at two or more consecutive measurements
| Participants | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 1: Placebo | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Number of Participants With Anti-HBs Seroconversion at Any Timepoint | 0 | 0 | 0 | 0 | 1 | 0 |
HBeAg loss is defined as quantitative HBeAg \< 0.14 IU/mL at two or more consecutive measurements. Anti-HBe seroconversion is defined as anti-HBe positivity at two or more consecutive measurements.
| Participants | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg | Part 2: Placebo |
|---|---|---|---|
| HBeAg loss | 0 | 0 | 0 |
| Anti-HBe seroconversion | 0 | 0 | 0 |
Collected over Up to 48 weeks after the first dose of VIR-2218 or placebo. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: VIR-2218 50 mg | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Part 1: VIR-2218 100 mg 100 mg | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Part 1: Placebo | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Part 2: VIR-2218 50 mg | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Part 2: VIR-2218 100 mg | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Part 2: Placebo | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Event | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg 100 mg | Part 1: Placebo | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/4 | 0/4 | 0/3 | 0/4 | 0/4 | 1/2 |
| DiarrhoeaGastrointestinal disorders | 0/4 | 0/4 | 0/3 | 1/4 | 0/4 | 0/2 |
| Epigastric discomfortGastrointestinal disorders | 0/4 | 0/4 | 0/3 | 1/4 | 0/4 | 0/2 |
| ToothacheGastrointestinal disorders | 1/4 | 0/4 | 0/3 | 0/4 | 0/4 | 0/2 |
| Decreased appetiteMetabolism and nutrition disorders | 0/4 | 0/4 | 0/3 | 0/4 | 1/4 | 0/2 |
| HyperuricaemiaMetabolism and nutrition disorders | 0/4 | 0/4 | 0/3 | 1/4 | 0/4 | 0/2 |
| FatigueGeneral disorders | 0/4 | 0/4 | 0/3 | 0/4 | 1/4 | 0/2 |
| Upper respiratory tract infectionInfections and infestations | 0/4 | 1/4 | 0/3 | 0/4 | 0/4 | 0/2 |
| Animal biteInjury, poisoning and procedural complications | 0/4 | 1/4 | 0/3 | 0/4 | 0/4 | 0/2 |
| SomnolenceNervous system disorders | 0/4 | 0/4 | 0/3 | 1/4 | 0/4 | 0/2 |
| Age, Continuous(years) | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 1: Placebo | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 48.5 ± 9.68 | 36.5 ± 9.26 | 31.0 ± 5.20 | 41.8 ± 4.27 | 39.5 ± 10.66 | 38.0 ± 11.31 | 39.7 ± 9.26 |
| Sex: Female, Male(Participants) | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 1: Placebo | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 1 | 1 | 1 | 3 |
| Male | 4 | 4 | 3 | 3 | 3 | 1 | 18 |
| Race (NIH/OMB)(Participants) | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 1: Placebo | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 4 | 4 | 3 | 4 | 4 | 2 | 21 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 1: Placebo | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| China | 4 | 4 | 3 | 4 | 4 | 2 | 21 |
| Baseline log10 hepatitis B surface antigen(log10 IU/mL) | Part 1: VIR-2218 50 mg | Part 1: VIR-2218 100 mg | Part 1: Placebo | Part 2: VIR-2218 50 mg | Part 2: VIR-2218 100 mg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 2.815 ± 0.4865 | 3.278 ± 0.7910 | 2.948 ± 0.4822 | 3.598 ± 0.5479 | 3.243 ± 0.4848 | 3.722 ± 0.0729 | 3.239 ± 0.5756 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2020 to primary completion in Sep 2021, 13 months.
Results were first posted in Aug 2024, 2 years 10 months after primary completion. A results delay was requested in Jul 2022.
Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 13 months is below that.
Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elebsiran
Brii Biosciences Limited